Aquestive Therapeutics, Inc. (AQST) Stock

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

Aquestive Therapeutics, Inc. is led by CEO Daniel Barber, employs 142 people, headquartered in US, publicly traded since 2018.

Aquestive Therapeutics, Inc. (AQST) stock trades at $4.00 with a market capitalization of $502.05M. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.09, reflecting a net loss over the last twelve months, a negative price-to-book of -10.18, reflecting negative shareholders' equity, price-to-sales of 10.69. Over the past 52 weeks the stock has ranged between $2.93 and $7.18, and currently trades 44.3% below its 52-week high.

On profitability, Aquestive Therapeutics, Inc. generates a return on equity (ROE) of 243.68% (not meaningful, as shareholders' equity is negative), return on capital employed of -45.62%, an operating margin of -155.56%, a net profit margin of -144.63%.

Official website: www.aquestive.com

Aquestive Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Aquestive Therapeutics, Inc. reported revenue of $52.0M rising to $45.0M, a change of -13.5% across 10 years. Compounded, revenue has grown -0.4% a year over five years, -2.1% over three, -22.4% over the last twelve months. Net profit fell to $-84.0M.

Operating margin went from -1.6% in 2016 to -156.4% in 2025, a fall of 154.7 percentage points. The most recent net margin is -144.63%. On a trailing twelve-month basis to Jun '26, revenue is $54.0M and net profit $-78.0M.

Borrowings rose from $39.0M to $131.0M, cash on hand is $98.0M, cash from operations was $-52.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged 92.0% over five years, and was 247.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Aquestive Therapeutics, Inc. (AQST) — frequently asked questions